ly3502970
Small moleculeexperimental
Clinical trial activity
47 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
25
Phase 3
23
Phase 4
0
Earliest trial started Jun 10, 2019 (NCT03929744)
Timeline
Indications
Studied for
- Atherosclerosis · Phase 3
- Cardiovascular Diseases · Phase 3
- Diabetes Mellitus, Type 2 · Phase 3
- Healthy Volunteers · Phase 1
- Hepatic Insufficiency · Phase 1
- Hypertension · Phase 3
- Obesity · Phase 3
- Osteoarthritis · Phase 3
- Overweight · Phase 3
- Peripheral Arterial Disease · Phase 3
- Renal Insufficiency · Phase 1
- Renal Insufficiency, Chronic · Phase 3
- Sleep Apnea, Obstructive · Phase 3
- Urinary Incontinence, Stress · Phase 3
Mechanism of action
- Glucagon-like peptide 1 receptorPARTIAL AGONIST
GLP1R partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F- Mol. weight
- 882.97 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4446782 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07241390 | Phase 3 | Jan 31, 2026 | Eli Lilly |
| NCT07223593 | Phase 3 | Oct 31, 2025 | Eli Lilly |
| NCT07202884 | Phase 3 | Sep 30, 2025 | Eli Lilly |
| NCT07153471 | Phase 3 | Sep 15, 2025 | Eli Lilly |
| NCT07152002 | Phase 1 | Aug 28, 2025 | Eli Lilly |
| NCT06972472 | Phase 3 | May 19, 2025 | Eli Lilly |
| NCT06993792 | Phase 3 | May 15, 2025 | Eli Lilly |
| NCT06972459 | Phase 3 | May 15, 2025 | Eli Lilly |
| NCT06948435 | Phase 3 | Apr 30, 2025 | Eli Lilly |
| NCT06952530 | Phase 3 | Apr 30, 2025 | Eli Lilly |
| NCT06948422 | Phase 3 | Apr 30, 2025 | Eli Lilly |
| NCT06824051 | Phase 1 | Feb 28, 2025 | Eli Lilly |
| NCT06672549 | Phase 3 | Dec 31, 2024 | Eli Lilly |
| NCT06672939 | Phase 3 | Dec 31, 2024 | Eli Lilly |
| NCT06692348 | Phase 1 | Dec 31, 2024 | Eli Lilly |
| NCT06704763 | Phase 1 | Dec 31, 2024 | Eli Lilly |
| NCT06649045 | Phase 3 | Oct 22, 2024 | Eli Lilly |
| NCT06584916 | Phase 3 | Sep 13, 2024 | Eli Lilly |
| NCT06440980 | Phase 1 | Jun 24, 2024 | Eli Lilly |
| NCT06370728 | Phase 1 | May 6, 2024 | Eli Lilly |
Showing 20 of 47 trials
Page 1 / 3